The earnings call reflected strong revenue growth and positive business development, with significant additions to the product portfolio and an increased financial outlook. However, challenges such as a decline in gross margin, a net loss from investments, and increased operating expenses were noted.

Company Guidance -

Q3 2025

During the Knight Therapeutics Second Quarter 2025 Results Conference Call, the company provided updated guidance for fiscal 2025, with expected revenues between CAD 410 million to CAD 420 million, up from the previous range of CAD 390 million to CAD 405 million. This increase is attributed to better-than-expected performance in the first half of the year and the addition of revenues from the Sumitomo transaction. The adjusted EBITDA is projected to remain at approximately 13% of revenues. Notably, for the first half of 2025, the company reported a record high adjusted revenue of CAD 197 million, driven by a 15% organic growth in their promoted product portfolio, and an adjusted EBITDA of CAD 27.6 million. In the second quarter alone, Knight delivered revenues of CAD 108.5 million, a 15% increase from the same quarter last year, with adjusted EBITDA reaching CAD 15.5 million or CAD 0.16 per share. Additionally, Knight has secured a $50 million revolving credit facility with National Bank and is in the process of expanding it to up to $100 million, with an additional accordion of $50 million, to support ongoing and future transactions.

Record High Adjusted Revenues

Knight Therapeutics achieved a record high adjusted revenues of CAD 197 million for the first half of 2025, driven by organic growth of 15% on a constant currency basis.

Strong Business Development

The company added over 50 products to its portfolio through Paladin and Sumitomo transactions, including five pipeline and early launch assets. Expanded agreements with Helsinn and Incyte added innovative pipeline products in oncology.

Significant Revenue Growth

Q2 2025 revenues were CAD 108.5 million, an increase of 15% compared to the same quarter last year. On a constant currency basis, revenues increased by 21%.

Increased Financial Outlook

Knight increased its fiscal 2025 revenue outlook to between CAD 410 million to CAD 420 million, up from CAD 390 million to CAD 405 million.

Revolving Credit Facility Secured

Knight secured a CAD 50 million revolving credit facility with National Bank and launched a syndication process to increase it to up to CAD 100 million, with an additional accordion of CAD 50 million.

Knight Therapeutics (KHTRF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KHTRF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	>-0.01 / -	0	―	―	―
Aug 07, 2025	2025 (Q2)	0.01 / -0.09	-0.014	-550.00% (-0.08)	―
May 08, 2025	2025 (Q1)	<0.01 / 0.01	-0.029	150.00% (+0.04)	―
Mar 20, 2025	2024 (Q4)	0.01 / 0.08	-0.167	147.83% (+0.25)	―
Nov 07, 2024	2024 (Q3)	0.01 / 0.00	0.065	―	―
Aug 08, 2024	2024 (Q2)	0.02 / -0.01	0.014	-200.00% (-0.03)	―
May 09, 2024	2024 (Q1)	<0.01 / -0.03	-0.029	0.00% (0.00)	―
Mar 21, 2024	2023 (Q4)	>-0.01 / -0.17	-0.094	-76.92% (-0.07)	―
Nov 09, 2023	2023 (Q3)	-0.02 / 0.07	0.007	800.00% (+0.06)	―
Aug 10, 2023	2023 (Q2)	>-0.01 / 0.01	0.014	0.00% (0.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KHTRF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$4.56	$4.66	+2.19%
May 08, 2025	$4.38	$4.08	-6.85%
Mar 20, 2025	$4.36	$4.39	+0.69%
Nov 07, 2024	$4.11	$3.73	-9.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Knight Therapeutics (KHTRF) report earnings?

Knight Therapeutics (KHTRF) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is Knight Therapeutics (KHTRF) earnings time?

Knight Therapeutics (KHTRF) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KHTRF EPS forecast?

KHTRF EPS forecast for the fiscal quarter 2025 (Q3) is >-0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing